Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/4/2020
SIETES contiene 92957 citas

 
 
<< anterior 21 a 40 de 396 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Linos E. Balancing the risks and benefits of rituximab. JAMA Intern Med 2013;173:920-37. [Ref.ID 95510]
22. Cita con resumen
van Boven JFM, de Jong-van den Berg LTW, Vegter S. Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf 2013;36:231-6. [Ref.ID 95311]
24. Cita con resumen
Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887-95. [Ref.ID 95064]
25. Cita con resumen
Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]
26. Cita con resumen
Anónimo. Tofacitinib (Xeljanz) for rheumatoid arthritis. Med Lett Drugs Ther 2013;55:1-3. [Ref.ID 94735]
27.Tiene citas relacionadas
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]
28.Tiene citas relacionadas
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]
29.Tiene citas relacionadas
Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012;380:1795-7. [Ref.ID 94115]
30.Tiene citas relacionadas Cita con resumen
Anónimo. Alemtuzumab for multiple sclerosis. Lancet 2012;380:1792. [Ref.ID 94114]
31. Cita con resumen
Martin-Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest 2013;144:258-65. [Ref.ID 93668]
32. Cita con resumen
Vehreschild JJ, Müller C, Farowski F, Vehreschild MJGT, Cornely OA, Fuhr U, Kreuzer K-A, Hallek M, Kohl V. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol 2012;68:987-95. [Ref.ID 93104]
33. Cita con resumen
Anónimo. FDA clears advanced-colorectal cancer treatment. DIA Daily 2012:28 de septiembre. [Ref.ID 93061]
36. Cita con resumen
Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA Drug Safety Surveillance Program: adverse event reporting trends. Arch Intern Med 2011;171:592. [Ref.ID 91171]
37.Tiene citas relacionadas
Samandari T, Agizeuw TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, Mosimaneotsile B, Motsamai OI, Bozeman L, Davis MK, Talbot EA, Moeti TL, Moffat HJ, Kilmarx PH, Castro KG, Wells CD. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:1588-98. [Ref.ID 90806]
38.Tiene citas relacionadas
Dodd LE, Wilkinson RJ. Isoniazid preventive therapy in HIV infection. Lancet 2011;377:1548-50. [Ref.ID 90803]
39. Cita con resumen
Andrews PJD, Avenell A, Noble DW, Campbell MK, Croal BL, Simpson WG, Vale LD, Battison CG, Jenkinson DJ, Cook JA, and the SIGNET (Scottish Intensive care Glutamine or seleNium Evaluative Trial) Trials Group. Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients. BMJ 2011;342:695. [Ref.ID 90344]
40. Cita con resumen
Anónimo. Treatment of Clostridium difficile infection. Med Lett Drugs Ther 2011;53:14-6. [Ref.ID 90242]
Seleccionar todas
 
<< anterior 21 a 40 de 396 siguiente >>